SHPH

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) SWOT Analysis Analysis (2026)

Invetso Score: 3.4/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

Negative ROIC indicates weaker capital efficiency than profitable peers, but the very low leverage profile limits balance-sheet drag versus more indebted competitors.

The extremely negative cash conversion cycle suggests supplier-funded working capital, which can support liquidity and operating flexibility relative to peers with cash-intensive cycles.

Weaknesses

Score:

ROIC of -3.1% shows the business is destroying value on invested capital, leaving it structurally behind peers that compound returns above their cost of capital.

Current and quick ratios of 0.30 indicate materially weaker short-term liquidity than peers, increasing dependence on external funding or operating cash inflows.

The near-zero debt load does not offset weak operating economics, because low leverage matters less when peers generate stronger margins and positive returns.

A cash conversion cycle of -708 days is unusually distorted, limiting comparability and suggesting working-capital quality is less reliable than peers with normal cycles.

Opportunities

Score:

If management normalizes working-capital mechanics, the unusually negative cash conversion cycle could release cash and improve liquidity faster than peers with longer cycles.

Any improvement in capital efficiency would have outsized impact because the current negative ROIC leaves substantial room to close the gap with profitable peers.

The low debt burden provides optionality to fund restructuring or growth initiatives without the balance-sheet constraints faced by more leveraged peers.

Threats

Score:

Persistent negative ROIC threatens long-term competitiveness, because peers with positive returns can reinvest more aggressively and widen the structural gap.

Weak liquidity ratios raise refinancing and execution risk, especially if operating cash flow underperforms peers during demand or cost shocks.

The distorted cash conversion cycle may mask underlying working-capital stress, making peer-relative performance harder to sustain if supplier terms normalize.

Overall Score

Score:

SHPH appears structurally weaker than peers overall, as negative capital returns and poor liquidity outweigh the limited support from low leverage and unusual working-capital dynamics.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Shuttle Pharmaceuticals Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →